高危非肌层浸润性膀胱癌的真实世界结局:BRAVO试验筛选患者分析
该研究连续纳入BRAVO随机对照试验(比较根治性膀胱切除术与卡介苗)筛选的193例高危非肌层浸润性膀胱癌患者,前瞻性登记并回顾病历获取结局,主要终点为总生存。结果显示全因死亡55例(28.5%),多因素分析中年龄>70岁、未以根治性膀胱切除术为首选治疗者总死亡风险更高;膀胱癌特异性死亡17例(8.8%),与初始治疗无关。
要点
- 高危非肌层浸润性膀胱癌患者死亡风险高,全因死亡55/193(28.5%)。
- 年龄>70岁者总死亡风险更高(HR 2.63,95%CI 1.35-5.13;Cox P=0.004)。
- 未以根治性膀胱切除术为首选治疗者总死亡风险更高(HR 2.16,95%CI 1.17-3.99;P=0.014)。
核心结论
- 高危非肌层浸润性膀胱癌患者 mortality 风险高,以根治性膀胱切除术作为初始治疗者死亡风险较低,但可能反映体能状态和选择偏倚。
研究设计与样本
- 连续纳入BRAVO随机对照试验(比较根治性膀胱切除术与卡介苗,ISRCTN12509361)筛选的患者,前瞻性登记,病历回顾获取结局,共193例。
主要发现
- 193例中106例(54.9%)接受卡介苗,43例(22.3%)行初始根治性膀胱切除术,37例(19.2%)接受其他治疗,7例(3.6%)接受膀胱内热灌注丝裂霉素C。
- 全因死亡55例(28.5%),中位(四分位距)随访29.0(19.5-42.0)个月。
- 多因素分析中,年龄>70岁总死亡风险更高(HR 2.63,95%CI 1.35-5.13;Cox P=0.004);来自地区医院者HR 0.53(95%CI 0.3-0.95;P=0.032);未以根治性膀胱切除术为首选治疗者HR 2.16(95%CI 1.17-3.99;P=0.014)。
- 膀胱癌特异性死亡17例(8.8%),中位(四分位距)22.5(19-36.25)个月;多因素分析中年龄>70岁HR 4.87(95%CI 1.1-21.6;P=0.037),Tis/T1期HR 2.26(95%CI 1.23-4.16;P=0.008),初始治疗间无差异。
局限性
- 结局通过病历回顾获取。
- 以根治性膀胱切除术作为初始治疗者死亡风险较低,但作者指出这可能反映体能状态和选择偏倚。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To report real-world outcomes for high-risk non-muscle-invasive bladder cancer (HRNMIBC), including bacillus Calmette-Guérin (BCG) and radical cystectomy (RC), as randomised comparisons of these have not been possible. METHODS: We detail consecutive participants screened for the BRAVO randomised controlled trial comparing RC with BCG (International Standard Randomised Controlled Trial Number [ISRCTN]12509361). Patients were prospectively registered and case-note review used for outcomes. The primary outcome was overall survival. Secondary outcomes included recurrence, progression, metastasis, and bladder cancer-specific survival. RESULTS AND LIMITATIONS: A total of 193 patients were screened, including 106 (54.9%) who received BCG, 43 (22.3%) primary RC, 37 (19.2%) 'other' treatment and seven (3.6%) hyperthermic intravesical mitomycin C. All-cause death occurred in 55 (28.5%) patients at median (interquartile range [IQR]) of 29.0 (19.5-42.0) months. In multivariable analysis, overall mortality was more common in older patients (hazard ratio [HR] 2.63, 95% confidence interval [CI] 1.35-5.13; Cox P = 0.004 for age >70 years), those recruited from district hospitals (HR 0.53, 95% CI 0.3-0.95; P = 0.032) and those who did not undergo RC as their first treatment (HR 2.16, 95% CI 1.17-3.99; P = 0.014). In all, 17 (8.8%) patients died from bladder cancer (BC) at median (IQR) of 22.5 (19-36.25) months. In multivariable analysis, BC-specific mortality was more common in older patients (HR 4.87, 95% CI 1.1-21.6; P = 0.037) and those with Tis/T1 disease (HR 2.26, 95% CI 1.23-4.16; P = 0.008) but did not vary with initial treatment. CONCLUSIONS: Patients with HRNMIBC are at high-risk of mortality. Those choosing RC as their initial treatment have lower risks of mortality than others, although this may reflect fitness and selection.
引用
- Conroy S, Jubber I, Noon AP, et al. Real-world outcomes for high-risk non-muscle-invasive bladder cancer: screened patients for the BRAVO trial. BJU Int. 2024. PMID: 39324506. doi:10.1111/bju.16516
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。